Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations
Recruiting · NCT07117890 · Interventional (participants receive a specific treatment) · Lead sponsor: Fudan University
View the official record on ClinicalTrials.gov →Interventions studied
sunvozertinib 200mgsunvozertinib 300mg
What this trial is about
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- ≥18 years old
- histologically or cytologically confirmed non-squamous NSCLC with documented EGFR uncommon mutations from a local laoratory. at least one EGFR uncommon mutation (excluding EGFR 19del/l858r/T790m/Ex 20ins ) or compund mutations with EGFR uncommon mutations.
- predicted life expectancy ≥ 12 weeks.
- patient must have measurable disease according to RECIST 1.1
Exclusion criteria
- previos systemic anti-tumor therapy
- a history of malignant tumors within 2years
- any severa or poorly controlled systemic disease per investigator's judgement
- active infections
Where it is running
1 location listed.
- Fudan university shanghai cancer center - Shanghai, China